Novo Nordisk A/S (NYSE:NVO) Upgraded by StockNews.com to Strong-Buy Rating

Novo Nordisk A/S (NYSE:NVO) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.

NVO has been the topic of several other research reports. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Up 1.3 %

Shares of Novo Nordisk A/S stock traded up $0.97 during midday trading on Thursday, reaching $75.76. 8,222,361 shares of the company’s stock traded hands, compared to its average volume of 5,380,158. The company has a market cap of $339.98 billion, a price-to-earnings ratio of 23.03, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company’s 50 day simple moving average is $84.15 and its 200 day simple moving average is $103.64.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Institutional investors have recently made changes to their positions in the business. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its position in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $29,000. Finally, Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $33,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.